# Ruhrlandklinik

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/ruhrlandklinik/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 80.5 |
| Citations | 224,215 |
| City | Essen |
| Country | DE |
| Description | Ruhrlandklinik is a research organisation in Essen, DE. OpenAlex records 4,818 works and 224,215 citations for it. 1,144 researchers list it as their most recent affiliation. |
| Homepage | http://www.ruhrlandklinik.de/ |
| OpenAlex ID | https://openalex.org/I4210089079 |
| Region | North Rhine-Westphalia |
| Researchers | 1,144 |
| ROR ID | https://ror.org/006c8a128 |
| Type | healthcare |
| Works | 4,818 |

## University papers

Showing 12 of 13.

- [Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-squamous-cell-non-small-cell-lung-cancer/)
- [Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial](https://scholariq.org/papers/cetuximab-plus-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer/)
- [Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-previously-treated-patients-with-advanced-non/)
- [Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057/)
- [Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial](https://scholariq.org/papers/pirfenidone-in-patients-with-progressive-fibrotic-interstitial-lung-diseases/)
- [The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.](https://scholariq.org/papers/the-wasog-sarcoidosis-organ-assessment-instrument-an-update-of-a-previous/)
- [2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up](https://scholariq.org/papers/2nd-esmo-consensus-conference-on-lung-cancer-early-stage-non-small-cell-lung/)
- [The IASLC Lung Cancer Staging Project](https://scholariq.org/papers/the-iaslc-lung-cancer-staging-project/)
- [Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)](https://scholariq.org/papers/phase-iii-study-of-surgery-versus-definitive-concurrent-chemoradiotherapy-boost/)
- [Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis](https://scholariq.org/papers/bronchoscopic-lung-cryobiopsy-increases-diagnostic-confidence-in-the/)
- [Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer](https://scholariq.org/papers/second-esmo-consensus-conference-on-lung-cancer-pathology-and-molecular/)
- [The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis](https://scholariq.org/papers/the-european-ipf-registry-euripfreg-baseline-characteristics-and-survival-of/)

## University top topics

Showing 8 of 25.

- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Tracheal and airway disorders](https://scholariq.org/topics/tracheal-and-airway-disorders/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Medical Imaging and Pathology Studies](https://scholariq.org/topics/medical-imaging-and-pathology-studies/)
- [Pleural and Pulmonary Diseases](https://scholariq.org/topics/pleural-and-pulmonary-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.